INGN
Company Description
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 348.67M | 335.70M | 315.66M | 377.24M | 358.00M | 308.49M | 361.94M | 358.11M | 249.44M | 202.83M | 159.00M | 112.54M |
| Net Income | (22.75M) | (35.89M) | (102.45M) | (83.77M) | (6.33M) | (5.83M) | 20.95M | 51.84M | 21.00M | 20.52M | 11.59M | 6.83M |
| EPS | -0.85 | -1.52 | -4.42 | -3.67 | -0.28 | -0.27 | 0.96 | 2.30 | 1.02 | 1.02 | 0.60 | 0.33 |
| Free Cash Flow | (21.60M) | (11.18M) | (29.75M) | (58.75M) | (302,000) | 19.67M | 34.08M | 47.00M | 50.27M | 23.02M | 25.67M | (540,000) |
| FCF / Share | -0.79 | -0.47 | -1.28 | -2.57 | -0.01 | 0.89 | 1.56 | 2.09 | 2.43 | 1.15 | 1.32 | -0.03 |
| Operating CF | (11.22M) | 5.91M | (3.23M) | (37.53M) | 23.63M | 37.01M | 40.59M | 59.98M | 60.49M | 31.03M | 38.16M | 15.70M |
| Total Assets | 298.62M | 296.19M | 326.19M | 405.04M | 489.51M | 461.85M | 447.34M | 375.90M | 275.07M | 214.05M | 161.31M | 140.09M |
| Total Debt | 17.48M | 19.41M | 21.92M | 23.28M | 26.67M | 10.01M | 6.72M | 0 | 0 | 0 | 315,000 | 614,000 |
| Cash & Equiv | 103.73M | 113.80M | 125.49M | 187.01M | 235.52M | 211.96M | 198.04M | 196.63M | 142.95M | 92.85M | 66.11M | 56.84M |
| Book Value | 192.23M | 173.86M | 204.81M | 297.41M | 370.23M | 349.62M | 344.62M | 310.42M | 227.04M | 182.09M | 134.02M | 118.15M |
| Return on Equity | -0.12 | -0.21 | -0.50 | -0.28 | -0.02 | -0.02 | 0.06 | 0.17 | 0.09 | 0.11 | 0.09 | 0.06 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 95.08M | 85.11M | 81.72M | 92.39M | 92.28M | 82.28M | 80.08M | 88.83M | 88.77M | 78.03M | 75.90M | 83.97M |
| Net Income | (3.85M) | (8.32M) | (7.13M) | (5.29M) | (4.15M) | (6.17M) | (9.76M) | (5.96M) | (5.59M) | (14.58M) | (26.55M) | (45.72M) |
| EPS | -0.14 | -0.30 | -0.26 | -0.20 | -0.15 | -0.25 | -0.41 | -0.25 | -0.24 | -0.62 | -1.14 | -1.97 |
| Free Cash Flow | 1.03M | (7.47M) | (3.31M) | 64,000 | 480,000 | (18.83M) | (6.16M) | 2.14M | 1.72M | (8.88M) | (9.45M) | (3.10M) |
| FCF / Share | 0.04 | -0.27 | -0.12 | 0.00 | 0.02 | -0.75 | -0.26 | 0.09 | 0.07 | -0.38 | -0.41 | -0.13 |
| Operating CF | 2.95M | (6.68M) | (943,000) | 2.17M | 4.35M | (16.79M) | (3.02M) | 6.99M | 6.69M | (4.75M) | (3.15M) | 2.19M |
| Total Assets | 285.57M | 285.93M | 298.62M | 307.01M | 312.04M | 308.41M | 296.19M | 306.17M | 308.92M | 315.60M | 326.19M | 343.70M |
| Total Debt | 15.79M | 16.93M | 17.48M | 18.22M | 19.04M | 19.21M | 19.41M | 20.15M | 21.44M | 22.11M | 21.92M | 22.77M |
| Cash & Equiv | 87.28M | 94.41M | 103.73M | 107.76M | 103.69M | 118.89M | 113.80M | 105.69M | 97.92M | 107.44M | 125.49M | 124.61M |
| Book Value | 174.86M | 182.91M | 192.23M | 197.18M | 199.49M | 197.95M | 173.86M | 185.40M | 187.59M | 191.90M | 204.81M | 230.63M |
| Return on Equity | -0.02 | -0.05 | -0.04 | -0.03 | -0.02 | -0.03 | -0.06 | -0.03 | -0.03 | -0.08 | -0.13 | -0.20 |
